0
Skip to Content
MD IP
Overseas patent firms
Corporates
Overflow support
Others
Working together
About me
Testimonials
Blog
Contact
md@md-ip.com
MD IP
Overseas patent firms
Corporates
Overflow support
Others
Working together
About me
Testimonials
Blog
Contact
md@md-ip.com
Folder: Services
Back
Overseas patent firms
Corporates
Overflow support
Others
Working together
About me
Testimonials
Blog
Contact
md@md-ip.com
Divisional applications at the European Patent Office
EPO practice, EPO prosecution Michał Dąbrówka 07/08/2025 EPO practice, EPO prosecution Michał Dąbrówka 07/08/2025

Divisional applications at the European Patent Office

There are several formal and practical aspects to keep in mind when filing divisional applications at the European Patent Office. Learn more in this article.

Read More
A guide to ‘further processing’ at the European Patent Office
EPO practice, EPO prosecution Michał Dąbrówka 31/07/2025 EPO practice, EPO prosecution Michał Dąbrówka 31/07/2025

A guide to ‘further processing’ at the European Patent Office

Beyond remedying missed deadlines, further processing can offer valuable flexibility during European patent prosecution. Learn how to leverage it effectively as part of a coordinated global filing strategy.

Read More
Parameters and (in)sufficiency of disclosure – T 2009/23
EPO case law, EPO oppositions and appeals, EPO T decisions Michał Dąbrówka 22/07/2025 EPO case law, EPO oppositions and appeals, EPO T decisions Michał Dąbrówka 22/07/2025

Parameters and (in)sufficiency of disclosure – T 2009/23

In T 2009/23, the Board of Appeal of the European Patent Office found that a key parameter in the main independent claim could not be reliably determined, leading to fatal insufficiency of disclosure.  Learn more in our latest article.

Read More
T 1065/23 – on novelty and inventive step of pea protein extracts
EPO case law, EPO T decisions, EPO practice Michał Dąbrówka 17/07/2025 EPO case law, EPO T decisions, EPO practice Michał Dąbrówka 17/07/2025

T 1065/23 – on novelty and inventive step of pea protein extracts

T 1065/23 from the EPO’s Technical Board of Appeal illustrates how targeted experimental evidence can make or break product-by-process claims in the chemical field. Learn more in our latest article.

Read More
T 1561/23 - G 1/24 in action
EPO case law, EPO G decisions, EPO T decisions Michał Dąbrówka 10/07/2025 EPO case law, EPO G decisions, EPO T decisions Michał Dąbrówka 10/07/2025

T 1561/23 - G 1/24 in action

In T 1561/23, the Technical Board of Appeal of the European Patent Office applied the principles of G 1/24 on using the description to interpret patent claims. Learn the key takeaways from the decision.

Read More
G 1/23 - reproducibility not a requirement for a commercial product to be prior art
EPO case law, EPO G decisions, EPO oppositions and appeals Michał Dąbrówka 03/07/2025 EPO case law, EPO G decisions, EPO oppositions and appeals Michał Dąbrówka 03/07/2025

G 1/23 - reproducibility not a requirement for a commercial product to be prior art

The Enlarged Board of Appeal finds in G 1/23 that non-reproducible commercial products are part of the state of the art. Learn the key takeaways here.

Read More
Newer Posts
Older Posts
Dark blue banner showing a white stylized dopamine molecule graphic to the left of the text “MD” in orange and “IP” in white.

Regulated by IP Reg.

Business Address

Zlota 75A/7
00-819, Warsaw
Poland

Contact

md@md-ip.com
+48 796 328 597